Group 1 - The company has announced a postponement of the board and supervisory board elections due to the recent completion of a specific A-share issuance project, ensuring continuity and stability in operations [1] - The current board and supervisory board members will continue to perform their duties until the new elections are completed, in accordance with relevant laws and regulations [1] - The postponement of the elections will not affect the normal operations of the company, and the company will expedite the election process and fulfill disclosure obligations [1] Group 2 - Independent director Chen Yamin has submitted his resignation after serving for six years, in compliance with relevant laws and regulations [2] - Chen Yamin's resignation will take effect only after the election of a new independent director at the shareholders' meeting, and he will continue to fulfill his duties until then [3] - The company expresses gratitude for Chen Yamin's contributions to its governance and development during his tenure [3]

Group 1 - The company announced the approval of a proposal to transfer 11.11% equity stake in Nanjing Tianshi Software Technology Co., Ltd. [1] - The board also approved a proposal to authorize internal loans to the company's wholly-owned subsidiary [1]

Group 1 - Yabont Chemical signed a 10-year supply strategic agreement with Jiangsu Hengrui Medicine to enhance collaboration in the pharmaceutical supply chain, effective from August 1, 2025 [1] - Wei Hua New Materials plans to acquire controlling interest in Jiangsu Heyutai Chemical to extend its product chain and improve competitiveness, currently in the planning stage [2] - Fujirey received a government subsidy of 2.0074 million yuan, expected to positively impact profits in 2025 [4] Group 2 - Hangzhou Garden won the land use rights for a plot in Yuhang District for 130 million yuan, planning to build a smart ecological design R&D headquarters with a total investment of no more than 450 million yuan [5] - Baotai's clinical trial for BAT5906, a recombinant anti-VEGF monoclonal antibody, received approval for new indications, aiming to accelerate commercialization [6] - Weisheng Information won multiple projects with a total bid amount of 110 million yuan, including significant contracts with Southern Power Grid and State Grid [8] Group 3 - Dong'an Power reported a 27.37% year-on-year increase in engine sales for July, totaling 34,500 units [13] - Hanma Technology's truck sales reached 956 units in July, marking a 42.69% year-on-year increase [14] - Jiangsu Bank's executives received regulatory approval for their positions, effective immediately [15] Group 4 - Chip Origin expects Q2 revenue of 584 million yuan, a 49.90% increase quarter-on-quarter, with significant growth in intellectual property licensing fees [24] - Dream Network Technology plans to establish a high-end equipment industry investment fund with a target fundraising of 2 billion yuan [26] - Hefei Urban Construction and China Real Estate Development won land use rights for a residential plot in Hefei for 980 million yuan [28] Group 5 - Lu Kang Pharmaceutical's subsidiary received a drug registration certificate for a new medication for erectile dysfunction [28] - Lifan Pharmaceutical's Mesalazine enteric-coated tablets received a drug registration certificate for treating ulcerative colitis [29] - Yahu Pharmaceutical's APL-1401 clinical trial for ulcerative colitis showed positive preliminary results [30]

开开实业（600272）(600272.SH)公告，公司拟通过上海联合产权交易所以公开挂牌转让的方式将所持 有的南京天石软件技术有限公司(简称"南京天石")11.11%股权进行转让。本次公开挂牌转让底价将不低 于1741.23万元。转让完成后公司将不再持有南京天石股权。 ...

格隆汇8月1日丨开开实业(600272.SH)公布，公司拟通过上海联合产权交易所以公开挂牌转让的方式将 所持有的南京天石软件技术有限公司(以下简称"南京天石")11.11%股权进行转让。经有证券期货业务从 业资格的资产评估机构预评估，以2024年12月31日为基准日，南京天石预评估价为人民币15,672.62万 元，本次公开挂牌转让底价将不低于公司所持有南京天石11.11%股权对应的预评估价值1,741.23万元。 ...

| 股票代码：600272 | 股票简称：开开实业 | | | 编号：2025—048 | | --- | --- | --- | --- | --- | | 900943 | | 开开 | 股 B | | 上海开开实业股份有限公司 关于拟转让南京天石软件技术有限公司 11.11%股权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 上海开开实业股份有限公司（以下简称"公司"）拟通过上海联合 产权交易所以公开挂牌转让的方式将所持有的南京天石软件技术有限公 司（以下简称"南京天石"）11.11%股权进行转让。经有证券期货业务从 业资格的资产评估机构预评估，以 2024 年 12 月 31 日为基准日，南京天 石预评估价为人民币 15,672.62 万元，本次公开挂牌转让底价将不低于公 司所持有南京天石 11.11%股权对应的预评估价值 1,741.23 万元。 本次交易不构成关联交易。 本次交易不构成重大资产重组。 本次交易已经公司第十届董事会第二十七次会议审议通过，无需 提交公司股东会审议，交易实施不 ...

的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会、监事会延期换届的情况 | 股票代码：600272 | 股票简称：开开实业 | | | 编号：2025-049 | | --- | --- | --- | --- | --- | | 900943 | | 开开 | B 股 | | 上海开开实业股份有限公司 关于董事会、监事会延期换届选举及独立董事任期届满 在公司新一届董事会、监事会换届选举工作完成前，公司第十届董事 会、监事会全体成员、董事会各专门委员会成员及高级管理人员将根据《中 华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所股票上 市规则》和《公司章程》的有关规定继续履行相应职责。 公司董事会、监事会延期换届选举不会影响公司的正常运营。公司将 按规定尽快推进董事会、监事会换届选举相关工作并及时履行信息披露义 务。 二、独立董事任期届满的情况 公司董事会收到独立董事陈亚民先生的书面辞职报告。陈亚民先生因 连续担任公司独立董事满六年，根据《中华人民共和国公司法》《上市公司 独立董事管理办法》 ...

| 股票代码：600272 | 股票简称：开开实业 | | | 编号：2025-047 | | --- | --- | --- | --- | --- | | 900943 | | 开开 | 股 B | | 上海开开实业股份有限公司 第十届董事会第二十七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海开开实业股份有限公司（以下简称"公司"）第十届董事会 第二十七次会议通知和会议相关材料于 2025 年 7 月 25 日以书面、电 话及电子邮件等方式发出，会议于 2025 年 8 月 1 日在公司会议室以 现场表决方式召开。本次会议应到董事 9 名，实到董事 9 名，3 名监 事及高级管理人员列席了会议。本次会议由董事长庄虔贇女士主持， 会议的召开程序符合《中华人民共和国公司法》与《公司章程》的有 关规定。会议审议通过了如下议案： 本次向全资子公司提供内部借款是为全力助推公司"大健康"战 略转型发展，满足全资子公司在"大健康"业务转型发展过程中的资 金需求，有利于促进其业务快速发展。本次内部借款资金来源为自有 ...

智通财经APP讯，开开实业(600272.SH)公告，公司拟通过上海联合产权交易所以公开挂牌转让的方式 将所持有的南京天石软件技术有限公司(简称"南京天石")11.11%股权进行转让。本次公开挂牌转让底价 将不低于1741.23万元。转让完成后公司将不再持有南京天石股权。 ...

Core Viewpoint - The company plans to transfer its 11.11% stake in Nanjing Tianshi Software Technology Co., Ltd. through a public listing on the Shanghai United Assets and Equity Exchange, with a pre-evaluation price of 157 million yuan [1] Group 1: Transaction Details - The minimum transfer price for the stake will not be less than 17.41 million yuan, which corresponds to the pre-evaluation value of the 11.11% stake [1] - After the transaction, the company will no longer hold any equity in Nanjing Tianshi [1] Group 2: Strategic Focus - This transaction is part of the company's strategy to concentrate resources on its core strengths and to implement a significant transformation towards the "big health" industry [1]